Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Temodex (temozolomide gel)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Belmedpreparaty, Double Bond Pharmaceutical

Drug class:

DNA synthesis inhibitor, Alkylating agent

Related drugs:

‹

cyclophosphamide intravenous (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

cyclophosphamide (66)

trabectedin (24)

lurbinectedin (11)

chlorambucil (7)

melphalan flufenamide (7)

procarbazine hydrochloride (4)

bendamustine RTD (2)

FGX15-147-based ADC (1)

bendamustine rapid infusion (0)

ranimustine (0)

carmustine implant (0)

altretamine (0)

mechlorethamine (0)

satraplatin (0)

mechlorethamine gel (0)

cyclophosphamide intravenous (0)

›

No biomarker	Astrocytoma	No biomarker	Astrocytoma	temozolomide gel Sensitive: A2 - Guideline temozolomide gel Sensitive : A2	temozolomide gel Sensitive: A2 - Guideline temozolomide gel Sensitive : A2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B
IDH2 mutation	Glioblastoma	IDH2 mutation	Glioblastoma	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3
TP53 mutation	Glioma	TP53 mutation	Glioma	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3
SETD2 mutation + MGMT promoter methylation	Glioblastoma	SETD2 mutation + MGMT promoter methylation	Glioblastoma	temozolomide gel Resistant: C3 – Early Trials temozolomide gel Resistant : C3	temozolomide gel Resistant: C3 – Early Trials temozolomide gel Resistant : C3
PIK3CA mutation + TTN mutation + IDH2 mutation	Glioma	PIK3CA mutation + TTN mutation + IDH2 mutation	Glioma	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3